Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Item: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Rating: 100
Author: Αlpha¹

Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 2 high issues for “Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions4

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized trial with strong methodological rigor across all eight dimensions. The paper provides clear scientific rationale, detailed methods, appropriate statistical analysis, and comprehensive reporting of ethics, data availability, and limitations. Minor reporting gaps (e.g., no explicit CONSORT statement, some internal inconsistencies in death counts) do not undermine the overall integrity.

Both reviewers independently scored all eight dimensions as 'pass' with high confidence, and their evidence was highly consistent. The study type is interventional (randomized phase 3 trial). The statistics verification covered only 2 tests (those with test statistics/CI), and the remaining statistics are unverified but not flagged. The citation check found no retracted or unresolved references. The integrity check flagged two low-severity internal contradictions (death counts differing between efficacy and safety sections) and one overstated claim in the claim audit.

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies (BEACON, ANCHOR) and explains the biological rationale for the combination. It acknowledges the limited efficacy of current first-line chemotherapies and the need for improved options. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on BRAF V600E-mutant mCRC, the rationale for combining BRAF/EGFR inhibition with chemotherapy, and the limitations of current first-line treatments.

Evidence

paraphrase[Introduction, paragraph 1-3]

“BRAF V600E mutations occur in 8–12% of metastatic colorectal cancers (mCRCs); the presence of these mutations has emerged as a distinct subtype that is characterized by poor prognosis compared with wild-type disease and resistance to standard chemotherapy regimens.”

direct quote[Introduction, paragraph 3]

“There are currently no first-line activation pathway-targeted treatments indicated for patients with BRAF V600E-mutant mCRC; therefore, a treatment that can demonstrate improved efficacy in the first-line setting is needed given the poor prognosis compared with BRAF wild-type mCRC.”